Immunotherapeutic strategies: The melanoma example

Immunotherapy

Volumn 1, Issue 4, 2009, Pages 679-690

  Jorritsma, Annelies ^a   Schumacher, Ton N M ^a   John Haanen, B A G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Adoptive transfer; Antigen; Melanoma; TCR gene transfer; Vaccination

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DNA VACCINE; INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; DERMATITIS; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; GENE TRANSFER; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOLOGICAL TOLERANCE; KIDNEY METASTASIS; LYMPHOCYTE FUNCTION; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE; THYROIDITIS; TREATMENT RESPONSE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; VULVA TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; NEOPLASM METASTASIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSGENES;

EID: 77953467619     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.20     Document Type: Review

References (124)

1. Lens MB, Dawes M: Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 150(2), 179-185 (2004).
2. Balch CM, Buzaid AC, Soong SJ et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635-3648 (2001).
3. Frisch M, Biggar RJ, Engels EA, Goedert JJ: Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13), 1736-1745 (2001). (Pubitemid 32259908)
4. Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33(3), 241-259 (1976).
5. Woglom WH: Immunity to transplantable tumors. Cancer Rev. 4, 129-214 (1929).
6. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005).
7. Zhang L, Conejo-Garcia JR, Katsaros D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
8. Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
9. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16), 3491-3494 (1998).
10. Marrogi AJ, Munshi A, Merogi AJ et al.: Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 74(5), 492-501 (1997). (Pubitemid 27486505)
11. + T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61(13), 5132-5136 (2001).
12. Clark WH Jr, Elder DE, Guerry D et al.: Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81(24), 1893-1904 (1989).
13. Clemente CG, Mihm MC Jr, Bufalino R et al.: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7), 1303-1310 (1996). (Pubitemid 26102328)
14. Mihm MC Jr, Clemente CG, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74(1), 43-47 (1996).
15. + T-cell immunity in disease progression of advanced-stage melanoma patients. Clin. Cancer Res. 10(14), 4754-4760 (2004).
16. van der Bruggen P, Traversari C, Chomez P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991). • Describes the identification of the first melanoma-associated antigen, which was an important stimulus for T-cell-based immunotherapy. (Pubitemid 21917508)
17. Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54(3), 187-207 (2005).
18. Parmiani G, De Filippo A, Novellino L, Castelli C: Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 178(4), 1975-1979 (2007).
19. Willimsky G, Blankenstein T: Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437(7055), 141-146 (2005). (Pubitemid 41613441)
20. De Plaen E, Arden K, Traversari C et al.: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40(5), 360-369 (1994). (Pubitemid 24299325)
21. Chen YT, Scanlan MJ, Sahin U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94(5), 1914-1918 (1997).
22. Derbinski J, Schulte A, Kyewski B, Klein L: Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2(11), 1032-1039 (2001).
23. Gotter J, Brors B, Hergenhahn M, Kyewski B: Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199(2), 155-166 (2004).
24. Brichard V, Van Pel A, Wolfel T et al.: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178(2), 489-495 (1993).
25. Bakker AB, Schreurs MW, de Boer AJ et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179(3), 1005-1009 (1994).
26. Coulie PG, Brichard V, Van Pel A et al.: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180(1), 35-42 (1994).
27. Kawakami Y, Eliyahu S, Delgado CH et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91(9), 3515-3519 (1994).
28. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181(2), 799-804 (1995).
29. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184(6), 2207-2216 (1996).
30. Nichols LA, Chen Y, Colella TA et al.: Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J. Immunol. 179(2), 993-1003 (2007).
31. Dunbar PR, Smith CL, Chao D et al.: A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165(11), 6644-6652 (2000).
32. Romero P, Valmori D, Pittet MJ et al: Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188, 81-96 (2002).
33. Zippelius A, Pittet MJ, Batard P et al.: Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195(4), 485-494 (2002).
34. Jager E, Nagata Y, Gnjatic S et al.: Monitoring CD8 T-cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA 97(9), 4760-4765 (2000).
35. Lee PP, Yee C, Savage PA et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5(6), 677-685 (1999).
36. Ikeda H, Lethe B, Lehmann F et al.: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2), 199-208 (1997). (Pubitemid 27145564)
37. Vierboom MP, Nijman HW, Offringa R et al.: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186(5), 695-704 (1997).
38. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10(6), 673-679 (1999).
39. Atkins MB, Lotze MT, Dutcher JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
40. Fyfe G, Fisher RI, Rosenberg SA et al.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
41. Rosenberg SA, Lotze MT, Muul LM et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313(23), 1485-1492 (1985). • Provides the first evidence for tumor regression upon immunotherapy.
42. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19(15), 3477-3482 (2001).
43. Rosenberg SA, White DE: Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis. Tumor Immunol. 19(1), 81-84 (1996).
44. Bakker AH , Schumacher TN: MHC multimer technology: current status and future prospects. Curr. Opin. Immunol. 17(4), 428-433 (2005).
45. Kirkwood JM, Manola J, Ibrahim J et al.: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670-1677 (2004).
46. Lens MB , Dawes M: Interferon alpha therapy for malignant melanoma: a systematic review of randomized controlled trials. J. Clin. Oncol. 20(7), 1818-1825 (2002).
47. Wheatley K, Ives N, Hancock B et al.: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev. 29(4), 241-252 (2003).
48. Gogas H, Ioannovich J, Dafni U et al.: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354(7), 709-718 (2006).
49. Ribas A, Camacho LH, Lopez-Berestein G et al.: Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23(35), 8968-8977 (2005).
50. Attia P, Phan GQ, Maker AV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043-6053 (2005).
51. Phan GQ, Yang JC, Sherry RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003). •• First report on cancer regression and autoimmunity upon treatment with anti-cytotoxic T lymphocyte-4 antibodies.
52. Hodi FS, Mihm MC, Soiffer RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100(8), 4712-4714 (2003).
53. Fischkoff SA, Hersh E, Weber J et al.: Durable responses and long-term progression-free suvival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J. Clin. Oncol. 23(16S), 7525 (2005).
54. Hersh EM, Weber JS, Powderly J D et al.: Disease control and long-term survival in chemotherapy-naïve patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine. J. Clin. Oncol. 26(15S), 9022 (2008).
55. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J. Exp. Med. 194(6), 823-832 (2001).
56. + regulatory T cells. J. Exp. Med. 202(7), 885-891 (2005).
57. Schepers K , Schumacher TN: Tumors hijack fetal enzyme, escape killer T cells. Nat. Med. 9(10), 1253-1254 (2003).
58. Bollard CM, Rossig C, Calonge MJ et al.: Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99(9), 3179-3187 (2002). (Pubitemid 34525296)
59. Lacuesta K, Buza E, Hauser H et al.: Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J. Immunother. 29(3), 250-260 (2006). (Pubitemid 44297293)
60. + T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65(5), 1761-1769 (2005).
61. + T cells. Cancer Res. 64(3), 1140-1145 (2004). (Pubitemid 38176921)
62. Iwai Y, Ishida M, Tanaka Y et al.: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
63. Stewart AJ , Devlin PM: The history of the smallpox vaccine. J. Infect. 52(5), 329-334 (2006).
64. Hsueh EC , Morton DL: Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin. Cancer Biol. 13(6), 401-407 (2003).
65. Sondak VK, Sosman JA: Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: melacine. Semin. Cancer Biol. 13(6), 409-415 (2003).
66. CancerVax Corporation media release, October 3, 2005. Data and Safety Monitoring Board Recommends Discontinuation of Canvaxin(TM) Phase 3 Clinical Trial for Patients with Stage III Melanoma. Also available from: www.micromet-inc.com
67. Sondak VK, Liu PY, Tuthill RJ et al.: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20(8), 2058-2066 (2002).
68. Bins A, Mallo H, Sein J et al.: Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. J. Immunother. 30(2), 234-239 (2007). (Pubitemid 46667803)
69. Lowe DB, Shearer MH, Jumper CA, Kennedy RC: Towards progress on DNA vaccines for cancer. Cell Mol. Life Sci. 64(18), 2391-2403 (2007).
70. Rice J, Ottensmeier CH, Stevenson FK: DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8(2), 108-120 (2008).
71. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
72. Terando AM, Faries MB, Morton DL: Vaccine therapy for melanoma: current status and future directions. Vaccine 25(Suppl. 2), B4-B16 (2007).
73. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5(4), 296-306 (2005).
74. Schadendorf D, Ugurel S, Schuler-Thurner B et al.: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17(4), 563-570 (2006).
75. Davis ID, Jefford M, Parente P, Cebon J: Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73(1), 3-29 (2003).
76. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ: Dendritic cell vaccination and immune monitoring. Cancer Immunol. Immunother. 57(10), 1559-1568 (2008).
77. de Vries IJ, Bernsen MR, Lesterhuis WJ et al.: Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 23(24), 5779-5787 (2005).
78. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199(6), 775-784 (2004).
79. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP: Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174(5), 2476-2480 (2005). (Pubitemid 40279657)
80. + T cells in melanoma patients. J. Immunother. 31(8), 781-791 (2008).
81. + T-cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115(3), 739-746 (2005).
82. Bins AD, Jorritsma A, Wolkers MC et al.: A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 11(8), 899-904 (2005).
83. + T cells. J. Immunol. 179(7), 4741-4753 (2007).
84. Verstrepen BE, Bins AD, Rollier CS et al.: Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared with intramuscular immunization in non-human primates. Vaccine (2008).
85. Teitz-Tennenbaum S, Li Q, Okuyama R et al.: Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J. Immunother. 31(4), 345-358 (2008). (Pubitemid 351595157)
86. Reits EA, Hodge JW, Herberts CA et al.: Radiation modulates the peptide repertoire, enhance MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med.. 203, 1259-1271 (2006).
87. + CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179(8), 5033-5040 (2007).
88. Bos R, van Duikeren S, Morreau H et al.: Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 68(20), 8446-8455 (2008).
89. Melief CJ, Welters MJP, Lowik MJG et al.: Long peptide vaccine-induced migration of HPV16-specific type 1 and 2 T cells into the lesions of VIN III patients associated with complete clinical responses. Cancer Immun. 7, 20 (2007)
90. Ley TJ, Mardis ER, Ding L et al.: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218), 66-72 (2008).
91. Rooney CM, Smith CA, Ng CY et al.: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345(8941), 9-13 (1995).
92. Walter EA, Greenberg PD, Gilbert MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333(16), 1038-1044 (1995).
93. Dudley ME, Wunderlich J, Nishimura MI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24(4), 363-373 (2001). (Pubitemid 32825868)
94. Dudley ME, Wunderlich JR, Yang JC et al.: A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25(3), 243-251 (2002).
95. Yee C, Thompson JA, Roche P et al.: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp.Med. 192(11), 1637-1644 (2000).
96. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99(25), 16168-16173 (2002).
97. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002). •• Important paper describing the only immunotherapeutic strategy that has resulted in substantial tumor regression in metastatic melanoma patients.
98. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
99. + T cells via TLR4 signaling. J. Clin. Invest. 117(8), 2197-2204 (2007). (Pubitemid 47219564)
100. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
101. Heemskerk B, Liu K, Dudley ME et al.: Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes gentically engineered to secrete interleukin-2. Hum. Gene Ther. 19(5), 496-510 (2008).
102. Godet Y, Moreau-Aubry A, Guilloux Y et al.: MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J. Exp. Med. 205(11), 2673-2682 (2008).
103. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26(4), 332-342 (2003). (Pubitemid 36858717)
104. Schumacher TN: T-cell-receptor gene therapy. Nat. Rev. Immunol. 2(7), 512-519 (2002).
105. Dembic Z, Haas W, Weiss S et al.: Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320(6059), 232-238 (1986). (Pubitemid 16040238)
106. Clay TM, Custer MC, Sachs J et al.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163(1), 507-513 (1999). (Pubitemid 29295880)
107. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD: Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74(17), 8207-8212 (2000). (Pubitemid 30641669)
108. Heemskerk MH, de Paus RA, Lurvink EG et al.: Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc. Natl Acad. Sci. USA 98(12), 6806-6811 (2001).
109. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI: Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin. Immunol. 98(2), 220-228 (2001).
110. Stanislawski T, Voss RH, Lotz C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2(10), 962-970 (2001).
111. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN: Immunotherapy through TCR gene transfer. Nat. Immunol. 2(10), 957-961 (2001).
112. De Witte MA, Coccoris M, Wolkers MC et al.: Targeting self-antigens through allogeneicTCR gene transfer. Blood 108(3), 870-877 (2006). (Pubitemid 44154619)
113. De Witte MA, Bendle GM, van den Boom MD et al.: TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J. Immunol. 181(4), 2563-2571 (2008).
114. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006). • First clinical study of T-cell receptor gene therapy for the treatment of melanoma, describing a modest but encouraging clinical response.
115. Johnson LA, Heemskerk B, Powell DJ Jr et al.: Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177(9), 6548-6559 (2006).
116. Romero P, Gervois N, Schneider J et al.: Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159(5), 2366-2374 (1997). (Pubitemid 127681029)
117. Coccoris M, De Witte MA, Schumacher TN: Prospects and limitations of T cell receptor gene therapy. Curr. Gene Ther. 5(6), 583-593 (2005).
118. Labrecque N, Whitfield LS, Obst R, Waltzinger C, Benoist C, Mathis D: How much TCR does a T cell need? Immunity 15(1), 71-82 (2001).
119. Jorritsma A, Gomez-Eerland R, Dokter M et al.: Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110(10), 3564-3572 (2007). (Pubitemid 350159623)
120. De Witte MA, Jorritsma A, Kaiser A et al.: Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol. 181(7), 5128-5136 (2008).
121. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA: Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66(17), 8878-8886 (2006). (Pubitemid 44449206)
122. Cohen CJ, Li YF, El Gamil M et al.: Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67(8), 3898-3903 (2007).
123. Kuball J, Dossett ML, Wolfl M et al.: Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109(6), 2331-2338 (2007). (Pubitemid 46425872)
124. Kaneko S, Mastaglio S, Bondanza A et al.: IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. 113(5), 1006-1015 Blood (2008).